This segment focuses on the research, development, and clinical evaluation of novel anti-cancer therapeutics. Key activities include preclinical studies, Phase 1, 1b/2, and Phase 3 clinical trials for drug candidates like oral rigosertib and ON 123300. The company utilizes small molecule drug discovery and development methodologies, targeting specific cellular pathways crucial for cancer cell proliferation. The therapeutic areas of focus are primarily in non-small cell lung cancer and recessive dystrophic epidermolysis bullosa. The goal is to improve patient outcomes by providing targeted therapies with the potential for fewer side effects and increased efficacy. Market positioning is as a clinical-stage biopharmaceutical company with a focus on innovative cancer treatments. Future opportunities include expanding the pipeline and securing regulatory approvals. Partnerships with companies like SymBio Pharmaceuticals Limited and Pint International SA support the development and commercialization efforts.